Pharma Focus Europe

Initial Patient Receives First Dose in Phase 2 MATISSE Trial Evaluating IPH5201 for Early Stage Lung Cancer

Monday, June 26, 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced the initiation of the MATISSE Phase 2 study (NCT05742607), a multicenter single-arm trial evaluating neoadjuvant and adjuvant treatment for resectable early stage non-small cell lung cancer (NSCLC) patients. The study aims to assess the antitumor activity and safety of IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy.

In collaboration with AstraZeneca, Innate Pharma will conduct the study and share the associated costs. AstraZeneca will supply the clinical trial drugs. The primary objectives of the trial are to evaluate pathological complete response (pCR) as a measure of antitumor activity and to assess the safety profile of the combination therapy.

Dr. Joyson Karakunnel, Chief Medical Officer at Innate Pharma, expressed satisfaction with the enrollment of the first patient in this Phase 2 study. He highlighted the potential of combining IPH5201 with durvalumab, chemotherapy, and adjuvant treatment for resectable early stage NSCLC patients. Dr. Karakunnel noted that if the combination demonstrates significant antitumor activity and good tolerability, as observed in the Phase 1 study, it would be a significant advancement in the development of IPH5201 for this indication.

Prof. Fabrice Barlesi, principal investigator of the study and an expert in the field of medicine, emphasized the unmet medical need for resectable early stage NSCLC patients who often experience relapse despite current treatment strategies. He explained that IPH5201 targets the CD39 immunosuppressive pathway, aiming to reduce immunosuppression and enhance antitumor immune responses in the tumor microenvironment. Prof. Barlesi expressed optimism about the ongoing enrollment and future results of the trial.

Further details about the MATISSE trial can be found on Innate Pharma has received a $5 million milestone payment from AstraZeneca upon the decision to advance IPH5201 to Phase 2 clinical trials.

IPH5201 is a blocking antibody that targets the CD39 immunosuppressive pathway present in the tumor microenvironment of various cancer types. CD39 inhibits the immune system by breaking down adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is further degraded into adenosine by CD73. By blocking CD39, IPH5201 aims to enhance antitumor activity by promoting the accumulation of immune-stimulating ATP and inhibiting the production of immune-suppressive adenosine.

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024